Drug Type Small molecule drug |
Synonyms 4-(3-(4-(1H-imidazo[4,5-b]pyridin-5-yl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride dihydrate, HTMC-0435, HTMC0435 |
Target |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Cholangiocarcinoma | Phase 2 | CN | 17 Oct 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 09 Oct 2023 | |
Pancreatic Cancer | Phase 2 | CN | 09 Oct 2023 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | CN | 03 Feb 2023 | |
Advanced Lung Small Cell Carcinoma | Phase 2 | CN | 11 Oct 2022 | |
Castration-Resistant Prostatic Cancer | IND Approval | CN | 28 Jul 2023 | |
Advanced Pancreatic Adenocarcinoma | IND Approval | CN | 07 Mar 2022 | |
Ovarian Cancer | IND Application | CN | 10 Dec 2019 | |
Prostatic Cancer | IND Application | CN | 10 Dec 2019 | |
Small Cell Lung Cancer | Preclinical | US | 09 Jan 2024 |